Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

EGFR G719S

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

EGFR G719S	Non Small Cell Lung Cancer	EGFR G719S	Non Small Cell Lung Cancer	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B
EGFR G719S	Non Small Cell Lung Cancer	EGFR G719S	Non Small Cell Lung Cancer	erlotinib Sensitive: C2 – Inclusion Criteria erlotinib Sensitive : C2	erlotinib Sensitive: C2 – Inclusion Criteria erlotinib Sensitive : C2
EGFR G719S	Non Small Cell Lung Cancer	EGFR G719S	Non Small Cell Lung Cancer	osimertinib Sensitive: C3 – Early Trials osimertinib Sensitive : C3	osimertinib Sensitive: C3 – Early Trials osimertinib Sensitive : C3
EGFR G719S	Lung Adenocarcinoma	EGFR G719S	Lung Adenocarcinoma	erlotinib Sensitive: C4 – Case Studies erlotinib Sensitive : C4	erlotinib Sensitive: C4 – Case Studies erlotinib Sensitive : C4
EGFR G719S	Colon Cancer	EGFR G719S	Colon Cancer	ABP 494 (cetuximab biosimilar) Sensitive: D – Preclinical ABP 494 (cetuximab biosimilar) Sensitive : D	ABP 494 (cetuximab biosimilar) Sensitive: D – Preclinical ABP 494 (cetuximab biosimilar) Sensitive : D
EGFR G719S	Colon Cancer	EGFR G719S	Colon Cancer	cetuximab Sensitive: D – Preclinical cetuximab Sensitive : D	cetuximab Sensitive: D – Preclinical cetuximab Sensitive : D
EGFR G719S	Colon Cancer	EGFR G719S	Colon Cancer	panitumumab Sensitive: D – Preclinical panitumumab Sensitive : D	panitumumab Sensitive: D – Preclinical panitumumab Sensitive : D